Open AccessThe effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
Author(s) -
L.A. Leiter,
S.C. Bain,
D.L. Bhatt,
J.B. Buse,
C.D. Mazer,
R.E. Pratley,
S. Rasmussen,
M.S. Ripa,
H. Vrazic,
S. Verma
Publication year - 2020
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/wedy-fx52
Subject(s) - semaglutide , liraglutide , medicine , blood pressure , baseline (sea) , glucagon like peptide 1 receptor , glucagon like peptide 1 , endocrinology , receptor , diabetes mellitus , agonist , type 2 diabetes , biology , fishery